Trials / Completed
CompletedNCT02187302
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (actual)
- Sponsor
- NewLink Genetics Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study to evaluate treatment in patients with metastatic renal cell carcinoma (RCC) which has progressed through 2 to 3 prior lines of therapy, with the investigational drug CRLX101 in combination with bevacizumab compared to treatment with a standard of care therapy. The study will compare which treatment resulted in longer time before progression of the RCC. Patients will be treated and followed for progression of their disease on average for up to 6 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CRLX101 | |
| DRUG | Bevacizumab | |
| DRUG | Standard of Care (Investigator Choice) |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2016-07-01
- Completion
- 2017-01-01
- First posted
- 2014-07-11
- Last updated
- 2020-05-28
Locations
43 sites across 2 countries: United States, South Korea
Source: ClinicalTrials.gov record NCT02187302. Inclusion in this directory is not an endorsement.